Pressmeddelande

BioStock: Ultimovacs shows positive three-year data in skin cancer

Cision Publicerad: 03 Nov 2022 08:47

Norwegian biotech Ultimovacs has recently presented positive three-year data for patients with metastatic malignant melanoma treated with cancer vaccine UV1 in combination with anti-PD-1 checkpoint inhibitor pembrolizumab. The results show both promising overall survival and an effect on predictive biomarkers, which strengthens the company's belief in UV1 as a combination treatment with today's checkpoint inhibitors for solid tumours. BioStock contacted Espen Basmo Ellingsen, Director Medical Affairst Ultimovacs, to find out more.

Read interview with Espen Basmo Ellingsen at biostock.se:

Ultimovacs shows positive three-year data in skin cancer - BioStock

This is a press release from BioStock - Connecting Innovation & Capital. https://www.biostock.se/en/

Nyheter om Ultimovacs

Läses av andra just nu

Innehåller annonslänkar. Investeringar innebär risk (se här)

Tips: 50% rabatt hos fondroboten Opti

Dags att komma igång med sparande? Fondroboten Opti erbjuder en populär spartjänst som är perfekt för regelbundet månadssparande. Just nu får nya kunder som använder Börskollens unika kampanjkod BORSKOLLEN50 automatiskt 50 % rabatt på Optis avgift i 3 månader!